Point-of-care diagnostics for infectious diseasesprimary
2 projects
Coordinated both DIADEM (low-cost diagnostics monitoring) and COMBO (dengue fever diagnostics platform), representing their core commercial product line.
Organization
BLUSENSE DIAGNOSTICS APS
Danish diagnostics SME developing rapid, low-cost biosensors for infectious diseases using nanotechnology and plasmonic detection.
Technology SMEhealthDKSMENo active H2020 projects
H2020 projects
4
As coordinator
2
Total EC funding
€2.4M
Unique partners
15
What they do
Their core work
BluSense Diagnostics is a Danish SME that develops low-cost, rapid diagnostic devices, with a strong focus on infectious disease detection. Their flagship effort centers on point-of-care diagnostics for dengue fever and other mosquito-borne diseases. They also contribute to research on nanotechnology-based biosensors, including endotoxin detection and colloidal particle design for biomedical applications.
Core expertise
What they specialise in
Nanotechnology-based biosensingsecondary
2 projects
Participated in ENDONANO (endotoxin detection via nanotechnology) and SuperCol (colloidal particle-based sensors), contributing diagnostic platform expertise to fundamental research.
Fluorescent and plasmonic detection systemsemerging
1 project
ENDONANO involved innovative fluorescent detection systems and plasmonics for bacterial endotoxin quantification, extending their sensor technology into new detection modalities.
Evolution & trajectory
How they've shifted over time
Early focus
Low-cost infectious disease diagnostics
Recent focus
Nanotechnology biosensors and colloidal particles
BluSense began with a clear commercial diagnostic focus — the 2015 DIADEM project was a feasibility study for low-cost diagnostics, followed by the much larger COMBO project to build a full dengue diagnostics platform. From 2019 onward, they shifted toward participating in research-oriented consortia (ENDONANO, SuperCol) that explore fundamental nanotechnology and colloidal science for biomedical sensing. This suggests a company that established its product base early and is now deepening its scientific foundations through academic collaborations.
BluSense is moving from pure product development toward deeper engagement with nanoscale detection science, likely to feed next-generation sensor capabilities back into their diagnostic platform.
Collaboration profile
How they like to work
Role: consortium_leaderReach: European9 countries collaborated
BluSense operates as both a project leader and a contributing partner. They coordinated their commercially-focused projects (DIADEM, COMBO) but joined as participants in the more research-oriented ENDONANO and SuperCol consortia. With 15 unique partners across 9 countries from just 4 projects, they build broad European networks rather than relying on a fixed set of repeat collaborators.
Despite being a small company with only 4 H2020 projects, BluSense has built a notably wide network of 15 partners across 9 countries, reflecting strong international connectivity for a diagnostics SME based in Copenhagen.
Why partner with them
What sets them apart
BluSense sits at the intersection of commercial diagnostic device development and academic nanotechnology research — a rare combination for a Danish SME. They bring real product development experience (point-of-care devices for tropical diseases) into research consortia, making them a credible bridge between lab science and market-ready diagnostics. For consortium builders, they offer both coordination experience and hands-on sensor engineering.
Notable projects
Highlights from their portfolio
- COMBOTheir largest project (EUR 1.93M) as coordinator, developing a complete diagnostics platform for dengue and mosquito-borne diseases — represents their core commercial ambition.
- SuperColParticipation in a fundamental colloidal science project signals strategic investment in next-generation particle-based sensor technology beyond their current product line.
Cross-sector capabilities
Nanotechnology and nanomaterialsFood safety and contamination detectionEnvironmental monitoring and biosensingTropical disease prevention
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →